



Episurf's implants market approved in Singapore

Episurf Medical (Nasdaq: EPIS B) today announces that the company's implants Episealer® Knee and Episealer® Talus have successfully gone through the medical devices product registration process of Singapore's Health Sciences Authority (HSA) and are approved for sale.

Episealer® Knee and Episealer® Talus are Episurf Medical's implants for the treatment of focal joint lesions in the knee and ankle, respectively.

"While the company has a focus on sales in the US and Europe, we still welcome approvals for sale in additional distribution markets, for increased dissemination of the company's technology", says Katarina Flodström, CEO, Episurf Medical.

For more information, please contact:

Katarina Flodström, CEO, Episurf Medical
Tel: +46 707 38 35 70
Email: katarina.flodstrom@episurf.com

About Episurf Medical

Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and individualised treatment alternatives. Episurf Medical's Episealer® individualised implants and Epiguide® surgical drill guides are developed for treating localised cartilage injury in joints. Episurf Medical's µFidelity® system enables implants to be cost-efficiently tailored to each individual's unique injury for the optimal fit and minimal intervention. Episurf Medical's head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company's website: www.episurf.com.

The information was submitted for publication, through the agency of the above contact person, at 08:45 CET on November 4, 2025.